Research & Development Market Research Reports & Industry Analysis
New product design and development is essential for the survival and growth of many companies, as markets and consumers’ tastes are fickle and the competition can be fierce. In order to stay relevant in a fast changing marketplace, firms have to constantly revise and expand their range of product offerings. Therefore, research and development is of great economic importance as companies fight to maintain their market share, though it may mean forgoing current profits in favor of potential future performance and returns.
Research and development is most often associated with the technology industry, as well as with science and in particular with healthcare and the development of new pharmaceuticals, diagnostics or medical devices that are safe and effective. For instance, drug makers must constantly search for the next big blockbuster drug, since the products they currently have on the market will eventually lose their patent protection and be vulnerable to generic competition. So they spend huge amounts of money on R&D because without a promising drug pipeline their revenue stream will ultimately dry up.
Research & Development Industry Research & Market Reports
-
CBD Gummies
... CAGR of 28.8% over the analysis period 2024-2030. Low, one of the segments analyzed in the report, is expected to record a 28.2% CAGR and reach US$32.4 Billion by the end of the analysis period. ... Read More
-
In Vivo Contract Research Organization (CRO)
... reach US$8.0 Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Smalll Molecules Modality, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and ... Read More
-
Colorectal Cancer Therapeutics
... at a CAGR of 6.5% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$14.9 Billion by the end of ... Read More
-
Pharmaceutical Contract Manufacturing
... at a CAGR of 5.2% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$93.8 Billion by the end of the ... Read More
-
Anemia Drugs
... CAGR of 4.1% over the analysis period 2024-2030. Iron Deficiency Anemia, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$7.4 Billion by the end of the ... Read More
-
e-Clinical Trial Technologies
... at a CAGR of 13.1% over the analysis period 2024-2030. Clinical Trial Management Systems (CTMS), one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$9.9 Billion by ... Read More
-
Rheumatoid Arthritis Diagnosis Tests
... 2030, growing at a CAGR of 5.8% over the analysis period 2024-2030. Diagnostic Laboratories End-Use, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$478.3 Million by ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
HIV Drugs
... CAGR of 5.2% over the analysis period 2024-2030. Combination HIV Medicines, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$29.0 Billion by the end of the ... Read More
-
Male Hypogonadism
... CAGR of 5.1% over the analysis period 2024-2030. Testosterone Replacement Therapy, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$3.5 Billion by the end of the ... Read More
-
Lymphoma Therapeutics
... CAGR of 6.5% over the analysis period 2024-2030. Non-Hodgkin Lymphoma (NHL), one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$20.5 Billion by the end of the ... Read More
-
Melanoma Therapeutics
... CAGR of 13.7% over the analysis period 2024-2030. Cutaneous Melanoma, one of the segments analyzed in the report, is expected to record a 13.7% CAGR and reach US$4.3 Billion by the end of the analysis ... Read More
-
Orphan Drugs
... CAGR of 12.0% over the analysis period 2024-2030. Biologic Drugs, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$308.5 Billion by the end of the analysis ... Read More
-
Non-alcoholic Steatohepatitis (NASH)
... at a CAGR of 55.7% over the analysis period 2024-2030. Vitamin E & Pioglitazone, one of the segments analyzed in the report, is expected to record a 45.3% CAGR and reach US$59.7 Billion by the ... Read More
-
Osteoporosis Therapeutics
... CAGR of 2.9% over the analysis period 2024-2030. Bisphosphonates, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$8.1 Billion by the end of the analysis period. ... Read More
-
Drug Discovery Technologies
... at a CAGR of 8.7% over the analysis period 2024-2030. Small Molecule Drugs, one of the segments analyzed in the report, is expected to record a 8.4% CAGR and reach US$92.7 Billion by the end ... Read More
-
Lung Cancer Therapeutics
... at a CAGR of 10.8% over the analysis period 2024-2030. Non-Small-Cell Lung Cancer (NSCLC), one of the segments analyzed in the report, is expected to record a 11.9% CAGR and reach US$82.3 Billion by the ... Read More
-
Legal Marijuana
... CAGR of 22.3% over the analysis period 2024-2030. Oil & Tinctures, one of the segments analyzed in the report, is expected to record a 23.4% CAGR and reach US$89.4 Billion by the end of the ... Read More
-
Medical Marijuana
... CAGR of 14.4% over the analysis period 2024-2030. Extract Form, one of the segments analyzed in the report, is expected to record a 14.7% CAGR and reach US$60.5 Billion by the end of the analysis ... Read More
-
mRNA Platform
... CAGR of -2.7% over the analysis period 2024-2030. Covid-19 Vaccine, one of the segments analyzed in the report, is expected to record a -6.3% CAGR and reach US$102.1 Billion by the end of the analysis ... Read More
-
Quantum Computing in Healthcare
... 2030, growing at a CAGR of 36.9% over the analysis period 2024-2030. Services, one of the segments analyzed in the report, is expected to record a 40.1% CAGR and reach US$452.4 Million by the end ... Read More
-
Preclinical Contract Research Organizations
... 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Toxicology Testing, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$3.2 Billion by the ... Read More
-
Contract Research Organization Services (CROs)
... Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Clinical Research, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$76.7 Billion ... Read More
-
Clinical Research (UK) - Industry Report
... the most attractive acquisition opportunities • Analyse industry trends • Benchmark their own financial performance Using an exclusive methodology, a quick glance of this Clinical Research (UK) report will tell you the companies that have ... Read More
-
Cannabis Production in Canada - Industry Market Research Report
... in 2013, producers have grown continuously as they invest in production capabilities to produce quality products. As consumers shifted from illegal cannabis purchases to the licensed recreational market, cannabis growers have grown significantly, but revenue ... Read More
Research Assistance
